Malaria Treatment & Artemisinin-Based Combination Therapies
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment. We supply the full EML-listed ACT range plus the parenteral and rectal artemisinins used in severe malaria and pre-referral care.
An artemisinin-based combination therapy (ACT) pairs a fast-acting artemisinin derivative with a longer-acting partner drug so that each protects the other against resistance. WHO recommends a three-day ACT course as the treatment of choice for uncomplicated P. falciparum malaria in all trimesters, and parenteral artesunate for severe malaria.
At a glance
- WHO recommends a three-day ACT course for uncomplicated falciparum malaria in all trimesters.
- The WHO Model List specifies six ACT combinations and their exact strengths.
- Parenteral artesunate at 2.4 mg/kg is the drug of choice for severe malaria; artemether is the intramuscular alternative.
- Rectal artesunate is for pre-referral use only — a single 10 mg/kg dose.
- We supply 15 antimalarial products across tablet, suspension, injection, suppository and granule forms.
01What the published guidance says
Every statement below is drawn from WHO or MSF published material and linked to its source. We summarise; we do not reproduce. Statements marked as our own are commercial positions, not clinical guidance.
ACT is the treatment of choice in all trimesters
For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine.
The ACT combinations and their strengths are specified on the WHO Model List
Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine.
For severe malaria, parenteral artesunate is the drug of choice
WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course.
Pre-referral rectal artesunate buys time in the first 24 hours
Because the risk of death from severe malaria is greatest during the first day, WHO recommends a single pre-referral dose by the parenteral or intrarectal route. Artesunate suppositories are given at 10 mg/kg as a single dose, in 50 mg or 200 mg formulations. The Model List carries a 100 mg rectal dosage form, restricted to pre-referral treatment of severe malaria only.
One combination to handle with care
MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase.
02Products in this therapeutic group
Each entry links to its full specification page.
| Product | Dosage form | Presentation notes | Detail |
|---|---|---|---|
| Artemether-Lumefantrine Suspension 180/1080mg | Suspension | View Artemether-Lumefantrine Suspension 180/1080mg → | |
| Artesunate Suspension 10mg/5mL 80mL | Suspension | Antimalarial | View Artesunate Suspension 10mg/5mL 80mL → |
| Artemether Suspension 15mg/5mL 60mL | Suspension | Antimalarial | View Artemether Suspension 15mg/5mL 60mL → |
| Artesunate 80mg Powder for Injection | Injection | Severe Malaria | View Artesunate 80mg Powder for Injection → |
| Quinine Dihydrochloride Injection | Injection | View Quinine Dihydrochloride Injection → | |
| Artemether/Lumefantrine 80/480mg | Tablet | View Artemether/Lumefantrine 80/480mg → | |
| Artesunate /Mefloquine 400mg/500mg | Tablet | View Artesunate /Mefloquine 400mg/500mg → | |
| Artesunate 200mg + Amodiaquine 600mg Tablets | Tablet | View Artesunate 200mg + Amodiaquine 600mg Tablets → | |
| Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg | Tablet | View Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg → | |
| Sulfadoxine/Pyrimethamine combined with Amodiaquine | Tablet | View Sulfadoxine/Pyrimethamine combined with Amodiaquine → | |
| Dihydroartemisinin 40mg and Piperaquine 320m | Tablet | View Dihydroartemisinin 40mg and Piperaquine 320m → | |
| Chloroquine Phosphate 500mg Tablets | Tablet | View Chloroquine Phosphate 500mg Tablets → | |
| Artesunate 20mg + Pyonaridine 60mg Granules | Granules | View Artesunate 20mg + Pyonaridine 60mg Granules → | |
| Artemether 80mg Injection | Injection | View Artemether 80mg Injection → | |
| Artesunate Suppositories 100mg | Suppository | Artemisinin Antimalarial Rectal Medication | View Artesunate Suppositories 100mg → |
15 products in this group · part of 186 finished dosage forms across 14 therapeutic areas.
03Specifying your order
The five things worth stating on a purchase order for this group, so the quotation comes back right first time.
Fixed-dose ratio
State the INN pair and ratio, e.g. artemether/lumefantrine 20/120 mg or 80/480 mg. Combination ratios are not interchangeable.
Blister configuration
ACTs are dispensed by weight band. Confirm the tablet count per blister and the pack that matches your national treatment guideline.
Dispersible or standard
Specify whether the paediatric presentation must be dispersible, and confirm the age or weight range it will be used for.
Injection reconstitution
For artesunate powder for injection, state the reconstitution volume expected, since dilution differs between the IV and IM routes.
Leaflet language
Patient information and prescribing leaflets must match the language your regulator requires for the destination market.
04How we supply it
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
Co-formulated and co-packaged
Fixed-dose combination tablets, dispersible paediatric tablets, dry suspensions and granules, plus the co-packaged artesunate – sulfadoxine/pyrimethamine presentation.
Parenteral and rectal
Artesunate powder for injection, artemether oily injection and artesunate suppositories for pre-referral use.
Paediatric-first
Weight-band dosing presentations suitable for national paediatric formularies, with dispersible options where the Model List specifies them.
Dossier-ready
COA, HPLC/GC data, stability packages, DMF and registration support for national antimalarial marketing-authorisation filings.
05Safety, labelling & regulatory notes
Points worth carrying into your tender, label review or clinical briefing.
- Artesunate for injection is a powder for reconstitution — confirm reconstitution volume, because the dilution differs between the intravenous (10 mg/mL) and intramuscular (20 mg/mL) routes.
- Artesunate suppositories are indicated only as a single pre-referral dose, never as definitive treatment. Referral must follow as soon as possible.
- Do not use AS/MQ where neurological signs appeared during the acute phase; do not use AS/SP in HIV-infected women on co-trimoxazole preventive therapy.
- Artesunate is a WHO-listed medicine with documented falsified circulation in some supply chains — verify batch documentation and the manufacturer's authorisation for your market.
06Questions buyers ask
6 answers covering specification, documentation and regulatory questions for this group.
What is the difference between artesunate and artemether for injection?
Which ACT combinations appear on the WHO Model List?
Do you supply dispersible paediatric ACTs?
Can you support registration in my market?
What strengths of artemether/lumefantrine do you supply?
Why can artemether not be given intravenously?
07Related therapeutic areas
Adjacent groups you may want to combine on one purchase order.
Request a quotation for Malaria & ACTs
Send us the products, strengths and pack sizes you need, together with the destination country, and we will return a quotation with the documentation package and lead time. Registration support documents are provided with every order.
Request a quotation →